AZIYO BIOLOGICS INC. news, videos and press releases
For more news please use our advanced search feature.
AZIYO BIOLOGICS INC. - More news...
AZIYO BIOLOGICS INC. - More news...
- Elutia Announces Fourth Quarter and Full Year 2024 Financial Results: Strong Demand for EluPro™ in Pilot Launch Sets the Stage for Full Commercial Roll-Out
- Elutia to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, March 6, 2025
- Elutia Announces $15.0 Million Registered Direct Offering
- Elutia Announces Full Launch of EluPro™ Following Strong Initial Demand
- Elutia Announces EluPro™ GPO Agreement with Southern Strategic Sourcing Partners
- Elutia Awarded Cardiac Rhythm Management Devices Agreement with Premier, Inc.
- Elutia Announces Strong Third Quarter Results, Accelerating Toward Full Launch of EluPro® Antibiotic-Eluting BioEnvelope in 2025
- Elutia to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Elutia to Report Third Quarter 2024 Financial Results on Thursday, November 14, 2024
- Elutia to Present at the LD Micro Main Event XVII Conference on Wednesday, October 30
- Elutia Announces New Peer Reviewed Publication Highlighting the Robustness of EluPro™, Company’s Antibiotic-Eluting BioEnvelope for Implantable Devices
- Elutia Celebrates First Year
- Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
- Elutia to Participate in Upcoming Investor Conferences
- Elutia Announces Second Quarter 2024 Results
- Elutia Announces Full Exercise of Warrants Generating $15.7 Million in Gross Proceeds
- Elutia Appoints Ryan Marques, Ph.D., MBA as Vice President of Operations
- Elutia to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024
- Elutia to Present at the Emerging Growth Conference on Thursday, July 18
- Elutia Announces $13.26 Million Registered Direct Offering
- Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and Defibrillators
- Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024
- Elutia Announces First Quarter 2024 Results: SimpliDerm® Sales Increase 55%, CanGaroo®RM on Track for Second Quarter 2024 FDA Clearance
- Elutia to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
- Elutia to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1
- Elutia Reports Fourth Quarter and Full Year 2023 Financial Results: Anticipates CanGarooRM® Clearance Decision in First Half of 2024
- Elutia to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 7, 2024
- Elutia Regains Compliance with Nasdaq Listing Requirements
- Elutia Submits CanGarooRM® Antibiotic-Eluting Biomatrix for FDA Clearance
- Elutia Reports 26% Year-Over-Year Sales Growth of Proprietary Products and Strengthened Balance Sheet in Third Quarter 2023 Financial Results
